Synthetic Blood's Patent Application For Glucose Sensor Approved

Synthetic Blood International Inc. (Kettering, OH) has been issued a notice by the U.S. Patent and Trademark Office allowing all claims in a new patent application covering the Company's implantable glucose biosensor. In particular, the patent application, "Glucose Sensor," protects the Company's membrane-enzyme complex that regulates the availability of glucose, which permits accurate measurement of glucose levels with low ambient oxygen tension. The biosensor system is being developed for use in diabetic patients to continuously monitor blood glucose levels.

The patent is the fourth announced by SYBD in the past month. SYBD is also developing Oxycyte, a perfluorocarbon based blood substitute, and Fluorovent, a perfluorocarbon liquid ventilation product.

For more information: Joan Mahan, Synthetic Blood International Inc., telephone: 1-800-809-6054.